Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at Innate Killer Conference

Senti Biosciences will present clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference. The data includes results from the ongoing Phase I clinical trial of SENTI-202, a first-in-class CAR NK cell therapy designed to target CD33 and/or FLT3 while sparing EMCN-expressing healthy cells in adults with relapsed/refractory acute myeloid leukemia (AML). The presentations will highlight clinical activity and the therapy's logic-gated mechanism of action.